M2IP peptide inhibitor targets TRPM2 intramolecular interactions, significantly alleviating ischemic stroke in mice

The TRPM2 calcium-permeable cation channel acts as a crucial oxidative stress sensor, playing a significant role in various pathologies, particularly ischemic stroke. Its activation mechanism, involving cooperative engagement of N- and C-terminal domains, is distinct among TRP channels. Current small-molecule inhibitors often target conserved pore regions, leading to limited specificity and poor efficacy, which hinders their clinical translation. This gap highlights the need for novel therapeutic strategies that can precisely modulate TRPM2 activity without off-target effects.

Researchers designed a novel peptide inhibitor, M2IP, specifically targeting the unique inter-subunit interface (interface III) within TRPM2. In vitro, they employed electrophysiology and calcium imaging to assess M2IP's ability to suppress TRPM2-mediated currents and calcium influx. For in vivo evaluation, M2IP was administered in a mouse model of ischemic stroke. The primary endpoint for the animal study was the alleviation of brain injury, comparing M2IP-treated groups against controls, though specific doses, routes, or sample sizes were not detailed in the abstract.

The rationally designed peptide, M2IP, demonstrated potent inhibitory activity against TRPM2, exhibiting sub-micromolar inhibitory potency. Critically, M2IP displayed high selectivity over other TRP channels, suggesting a targeted mechanism of action. In vitro experiments confirmed its efficacy: electrophysiology and calcium imaging assays showed that M2IP effectively suppressed TRPM2-mediated currents and calcium influx. This indicates successful modulation of the channel's function at a molecular level. The most significant finding came from the in vivo studies:

M2IP treatment significantly alleviated brain injury in the mouse model of ischemic stroke. This preclinical evidence supports M2IP's potential as a therapeutic agent for neuroprotection, by directly targeting a key mediator of oxidative stress-induced damage.